Roche Holding AG
ROP
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,338.80 | 54.50 | -0.58% |
| CAC 40 | 8,462.39 | 23.19 | 0.27% |
| DAX 40 | 26,285.96 | 19.82 | 0.08% |
| Dow JONES (US) | 53,461.60 | 115.80 | -0.22% |
| FTSE 100 | 10,878.12 | 8.04 | -0.07% |
| HKSE | 25,652.97 | 141.87 | 0.56% |
| NASDAQ | 26,114.54 | 36.76 | -0.14% |
| Nikkei 225 | 66,262.16 | 405.73 | 0.62% |
| NZX 50 Index | 14,013.21 | 20.49 | 0.15% |
| S&P 500 | 7,675.54 | 1.74 | -0.02% |
| S&P/ASX 200 | 9,127.80 | 55.90 | -0.61% |
| SSE Composite Index | 3,912.52 | 23.08 | 0.59% |